Drug Interactions between Eliquis and Lynparza
This report displays the potential drug interactions for the following 2 drugs:
- Eliquis (apixaban)
- Lynparza (olaparib)
Interactions between your drugs
No interactions were found between Eliquis and Lynparza. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Eliquis
A total of 374 drugs are known to interact with Eliquis.
- Eliquis is in the drug class factor Xa inhibitors.
-
Eliquis is used to treat the following conditions:
- Deep Vein Thrombosis
- Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery
- Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery
- Deep Vein Thrombosis, Prophylaxis
- Prevention of Thromboembolism in Atrial Fibrillation
- Pulmonary Embolism
- Thromboembolic Stroke Prophylaxis
- Venous Thromboembolism
Lynparza
A total of 567 drugs are known to interact with Lynparza.
- Lynparza is in the drug class PARP inhibitors.
- Lynparza is used to treat the following conditions:
Drug and food interactions
olaparib food
Applies to: Lynparza (olaparib)
GENERALLY AVOID: Grapefruit juice may significantly increase the plasma concentrations of olaparib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In a drug interaction study with 57 patients, olaparib systemic exposure (AUC) was increased approximately 2.7-fold by the potent CYP450 3A4 inhibitor itraconazole. Simulations using physiologically-based pharmacokinetic (PBPK) models suggest that a moderate inhibitor (fluconazole) may increase the AUC of olaparib by 2-fold. The interaction has not been studied with grapefruit juice. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.
MANAGEMENT: Patients treated with olaparib should avoid consumption of grapefruit, grapefruit juice, starfruit (carambola), and Seville oranges.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2014) "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.